A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
dc.contributor.author | Mikhael, Joseph | |
dc.contributor.author | Belhadj-Merzoug, Karim | |
dc.contributor.author | Hulin, Cyrille | |
dc.contributor.author | Vincent, Laure | |
dc.contributor.author | Moreau, Philippe | |
dc.contributor.author | Gasparetto, Cristina | |
dc.contributor.author | Pour, Ludek | |
dc.contributor.author | Spicka, Ivan | |
dc.contributor.author | Vij, Ravi | |
dc.contributor.author | Zonder, Jeffrey | |
dc.contributor.author | Atanackovic, Djordje | |
dc.contributor.author | Gabrail, Nashat | |
dc.contributor.author | Martin, Thomas G | |
dc.contributor.author | Perrot, Aurore | |
dc.contributor.author | Bensfia, Samira | |
dc.contributor.author | Weng, Qilong | |
dc.contributor.author | Brillac, Claire | |
dc.contributor.author | Semiond, Dorothée | |
dc.contributor.author | Macé, Sandrine | |
dc.contributor.author | Corzo, Kathryn P | |
dc.contributor.author | Leleu, Xavier | |
dc.date.accessioned | 2021-05-17T14:29:29Z | |
dc.date.available | 2021-05-17T14:29:29Z | |
dc.date.issued | 2021-05-12 | |
dc.identifier.uri | http://hdl.handle.net/10713/15660 | |
dc.description.uri | https://doi.org/10.1038/s41408-021-00478-4 | en_US |
dc.description.uri | http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8116334/ | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer Nature | en_US |
dc.relation.ispartof | Blood Cancer Journal | en_US |
dc.subject | isatuximab | en_US |
dc.subject.mesh | Multiple Myeloma--drug therapy | en_US |
dc.title | A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1038/s41408-021-00478-4 | |
dc.identifier.pmid | 33980831 | |
dc.source.volume | 11 | |
dc.source.issue | 5 | |
dc.source.beginpage | 89 | |
dc.source.endpage | ||
dc.source.country | United States |